Viking Therapeutics has announced positive results from a Phase 2 study of its experimental obesity drug, VK2735, which showed patients losing up to nearly 15% of their weight over about three months. The drug, a dual agonist of GLP-1 and GIP receptors, demonstrated significant weight loss of up to 14.7% after 13 weeks, positioning Viking as a formidable competitor against established players like Eli Lilly and Novo Nordisk in the rapidly growing obesity drug market, expected to reach $100 billion by decade's end. Viking's stock soared, closing up $46.57, an increase of 121% to $85.05, following the announcement. Additionally, about one-fifth of the 105 obesity treatments currently in development or on the market are being investigated for the fatty liver disease MASH, indicating the broader therapeutic potential of these drugs.
Viking Therapeutics obesity drug hits target in key study, raising hopes for a competitor to existing medicines https://t.co/QVzKgtdkbq via @DrewQJoseph for @statnews
Viking Therapeutics claims to be developing the most potent anti-obesity therapeutic to date—VK2735. Top-line results from the Ph1 trial for their experimental incretin therapy yielded 13.1% weight loss at 13 weeks. 🤯 https://t.co/Hk1GYx1HL3
Viking Therapeutics claims to be developing the most potent anti-obesity therapeutic to date—VK2735. Top-line results from the Ph1 of their experimental incretin therapy yielded 13.1% weight loss at 13 weeks. 🤯 https://t.co/Hk1GYx1HL3
Viking Therapeutics claim to be developing the most potent anti-obesity therapeutic to date—VK2735. Top-line results from the Ph1 of their experimental incretin therapy yielded 13.1% weight loss at 13 weeks. 🤯 https://t.co/Hk1GYx1HL3
$VKTX closed up $46.57, +121% to $85.05 today. Coincidentally Viking Global loved Viking Therapeutics the most among hedge fund holders. The top tiger cub hedge fund loaded up $VKTX shares 4 quarters in a row to hold total 5.14M+ as of 12/31. 👇🏼🔥 https://t.co/HtIjt7Dcew https://t.co/At3F02gI0O
Yeah, so Viking Therapeutics $VKTX blew right past the moon today. Jumped OVER 121% after releasing promising clinical results of an experimental weight loss drug. Sector ETF $XBI up over +5.57%, with big moves across other names as well. Iron condor did not handle it well :') https://t.co/t23HiX6hf0
Positive Phase II data for #GLP-1 #GIP agonist #VK2735 may position @Viking_VKTX as the next major M&A target in #obesity $VKTX $LLY $NVO https://t.co/eY57HZlCKj
After a move of 121% higher on Tuesday, what's next for $VKTX and its shareholders? @Oppenheimer Biotech Analyst Jay Olson delivers his thoughts on the company's weight loss drug-fueled surge: https://t.co/PMdS1pQj3k
Viking Therapeutics' obesity drug succeeds in key study, helping patients lose up to nearly 15% of their weight over about three months. https://t.co/JIRH9EKYzP
Viking Therapeutics stock soars on robust weight loss drug data https://t.co/eKKJcoBvtO ⬆️ $VKTX +121.02% https://t.co/7Z20dQRZH9
Viking Therapeutics $VKTX ended the day up 120%! Cathie probably missed her chance to enter the GLP-1 trade! $LLY $NVO https://t.co/YX8O03gFhU
Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from https://t.co/spOFqBfaeK
Viking Therapeutics posted results of an experimental drug that showed even better weight loss than the current market-leading drugs, a sign that the dominance of Ozempic and Mounjaro is far from assured. https://t.co/OotL65Dovs
Viking Therapeutics soars 104% after its GLP-1 weight-loss drug posts impressive results in Phase 2 trial https://t.co/7djrdzEMWC
Keep in mind $VKTX 🚀🚀 had much better results than $LLY This is huge if true 👇 https://t.co/Vmq0XJuKho
Viking data suggest obesity drug could rival Zepbound, Wegovy https://t.co/OB8tB3XNhR $VKTX @ByJonGardner
$VKTX doubled in value as analysts gave a thumbs up to PhII obesity data that could ultimately edge out $LLY. That would take a sizably bigger partner to accomplish, which is likely what the punters are after now. Good luck with that -- in this field, sky's the limit but look…
Companies in the obesity market are striving to prove that their drugs offer unique benefits beyond weight loss. The fatty liver disease MASH is the next target. https://t.co/mlo1Ok6wTh
Viking Therapeutics shares more than double on ‘statistically significant’ weight-loss trial results https://t.co/FJ9ewNRj2K
Viking data suggest obesity drug could rival Zepbound, Wegovy https://t.co/IGSWJ8B77O @ByJonGardner $VKTX + 90% $LLY $NVO
A new update of STAT's Obesity Drug Tracker shows that at about one-fifth of the 105 obesity treatments in development or on the market are also being investigated for the fatty liver disease known as MASH. https://t.co/1cVbUFvRKm
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition as the competition in the broader obesity medicine field pushes ahead. https://t.co/mhNzsidIx1
Viking has plenty to celebrate after its dual agonist of GLP-1 and GIP was linked to weight loss of up to 14.7% after 13 weeks. $VKTX https://t.co/yjUhFWHguR
Viking Therapeutics $VKTX emerges as a competitor to $LLY and $NVO. The company has disclosed that its phase 2 trial of VK2735, which is being developed to potentially treat obesity, reached its primary endpoint and all secondary endpoints. People that were given VK2735 showed… https://t.co/7LWyzDkf6F
Viking Therapeutics' weight-loss drug trial success spurs share surge https://t.co/XLxFtMvSAe https://t.co/S9PHeMUEBg
Viking Therapeutics $VKTX stock is up +90% after they reported positive results in the trial of a weight-loss drug. The trial met all primary and secondary endpoints. #stocks https://t.co/Y0NelqVbFi
Viking Therapeutics shares doubled in early trading after the company said its experimental obesity drug delivered positive results in a mid-stage trial. https://t.co/ltZwoIi3r6
$VKTX up 80%+ over positive drug trials for weight loss drug. Viking to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade https://t.co/TBDIFMbbRC
Viking Therapeutics stock jumps 80% after positive weight loss drug trial results https://t.co/8BVtKBfdx5
An obesity drug from Viking Therapeutics succeeded in a Phase 2 study, helping patients lose nearly 15% of weight and further fueling the competition in the obesity market. https://t.co/dCfEv2HgUV
$VKTX --> Obesity drug from Viking Therapeutics hits target in Phase 2 study, raising hopes for a competitor to existing medicines https://t.co/M3o0aILQY1 via @DrewQJoseph
Think $VKTX data affirms the importance of the GIP axis whether you think it is agonism or antagonism. It is not just a “super-GLP-1” https://t.co/uySfbO0BoP
$VKTX Boom Boom $83 pre-mkt 🚀🚀 positive results in trial of weight-loss drug. https://t.co/mzWnS10bzT https://t.co/AxX6453rLl
$VKTX looks like a nice $15-20B acquisition for a pharma company that wants to compete against $LLY
$VKTX good to see #biotech take market share from Big Pharma in #obesity. Glp1 used to be almost a headwind to the space (MASH, CVD etc), now tides are shifting.
$VKTX (+108.3% pre) Viking Therapeutics’ stock soars premarket after company reports positive results in trial of weight-loss drug - MW https://t.co/VB7tquunk3
Trial of weight-loss drug sends Viking Therapeutics stock soaring https://t.co/pOLd43M31m
Viking Therapeutics’ stock soars 61% premarket after company reports positive results in trial of weight-loss drug https://t.co/9WHh8t4VMb
$VKTX 🇺🇸 Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity https://t.co/cfCqAhGylM https://t.co/wW9LHU9a1C
News on Boehringer & Zealand Pharma's experimental obesity drug in clinical trial: "The study result is the latest evidence new weight loss drugs that affect insulin production could help people with a common liver disease, too." https://t.co/uwU4fHOK0q
Researchers are looking at the obesity drugs in development as a way of addressing the fatty liver disease MASH. https://t.co/yHBpSxXp5t
About 1 in 5 obesity drugs in development/on the market are being investigated for the liver disease MASH, according to a new analysis using our obesity drug tracker: https://t.co/Uc0r46BTRQ
Liver disease MASH is next target for obesity drugs in development reports @elaineywchen, along with a fresh update to STAT's Obesity Drug Tracker https://t.co/q40ED1x4RE via @statnews
Liver disease MASH is next target for obesity drugs in development https://t.co/lpKabd4BDI
With competition flaring, obesity drug hits goal in liver disease study https://t.co/Dwb2SoKXs6
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the obesity medicine field pushes ahead. https://t.co/ae1YojRxaG
Obesity treatment from Boehringer Ingelheim, Zealand Pharma $ZEAL succeeds in study in liver condition MASH https://t.co/ryllXbgTrM via @DrewQJoseph